Text
Gonadotoxic Effect of Gombined Chemotherapy on Anti Miilerian Hormone (AMH) Level in non-Gynecologic Cancer Patients in Reproductive Age
Objective: To assess the effect of combined chemotherapy on levels of Anti-Mullerian Hormone (AMH).
Metbod: This is a prospective cohort study on 12 non-gyne-cologic cancer women aged 20 - 40 years who received combined chemotherapy treatment. AMH levels and menstrual pattern before and after three months of chemotherapy were examined. The rela-tionships between age, chemotherapy regimens and the cumulative doses on the change of AMH were also analyzed.
Result: The median age of subjects was 37 years (range 20 - 40 years). Pre chemotherapy AMH analysis revealed an inverse corre¬lation between age and AMH levels (r = -0.715; p = 0.009). AMH levels after 3 months of combined chemotherapy drastically de¬clined to 84.6% (p = 0.002). Multivanate analysis indicated that age and total cumulative dose were the main factors contributing to the AMH levels reduction (r = -0.679; P = 0.002 and r = 0.405; P = 0.027). Ten of 12 subjects (83.3%) experienced amenorrhea after 3 months of chemotherapy and had lower level of pre and post¬chemotherapy AMH compared to those who still maintained normal periods (p ~ 0.03 and 0.02).
Conclusion: AMH levels in non-gynecological cancer women who received combined chemotherapy decreased dramatically after 3 months of chemotherapy. Main factors that contribute to this were the cumulative dose and age. Most of these subjects experienced amenorrhea after 3 months of chemotherapy.
No other version available